Prapela SVS Pivotal Clinical Trial
Randomized Clinical Trial
Efficacy of a Vibrating Crib Mattress to Reduce Pharmacologic Treatment in Opioid-Exposed Newborns: A Randomized Clinical Trial.
JAMA Pediatrics. 2023;177(7):665–674.
PMID: 37003713
https://doi.org/10.1001/jamapediatrics.2023.1077
⚕ Trial conducted under Finnegan assessment: SVS-treated infants met discharge threshold of ≤8 on Finnegan Neonatal Abstinence Scoring. This is the pivotal trial underlying Prapela's FDA De Novo authorization.
Prapela SVS Supporting Clinical Trial
Foundational Research
Vibrotactile Stimulation: A Non-pharmacological Intervention for Opioid-Exposed Newborns.
PLoS ONE. 2017;12(4):e0175981.
PMID: 28437438
https://doi.org/10.1371/journal.pone.0175981
Foundational SVS Research
Multicenter RCT · NOWS
Efficacy of Stochastic Vibro-Tactile Stimulation for Newborns at Risk of Neonatal Opioid Withdrawal Syndrome.
Pediatric Research. 2025.
Pilot Study · NOWS
Physiologic Dysregulation in Newborns with Prenatal Opioid Exposure: Cardiac, Respiratory and Movement Activity.
Neurotoxicology and Teratology. 2022;92:107105.
PMID: 35636615
https://doi.org/10.1016/j.ntt.2022.107105
Clinical Study · AOP
Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial.
Pediatrics. 2015;136(6):e1561–e1568.
PMID: 26527547
https://doi.org/10.1542/peds.2015-1334
Clinical Study · AOP
Stabilizing Immature Breathing Patterns of Preterm Infants Using Stochastic Mechanosensory Stimulation.
Journal of Applied Physiology. 2009;107(4):1017–1027.
PMID: 19608934
https://doi.org/10.1152/japplphysiol.00058.2009
Foundational · First Clinical Observation
Sporadic Apnea: Paradoxical Transformation to Eupnea by Perturbations that Inhibit Inspiration.
Medical Hypotheses. 1997;49(1):19–26.
PMID: 9247914
https://pubmed.ncbi.nlm.nih.gov/9247914/
Foundational · Mechanism
Dysrhythmias of the Respiratory Oscillator.
Chaos. 1995;5(1):18–29.
PMID: 12780150
https://doi.org/10.1063/1.166067
Neonatal Opioid Withdrawal Syndrome: Supporting Clinical Literature
Critical Reassessment — Lead Article
Reassessing the Eat, Sleep, Console Protocol: Evidence Gaps and Implications for Neonatal Opioid Withdrawal Syndrome Management.
Pediatric Research. 2026.
⚠ This paper critically reassesses ESC's evidence base, arguing that reductions in LOS may reflect reduced pharmacological weaning rather than improved outcomes, and that long-term neurodevelopmental data remain lacking. SVS is compatible with both Finnegan and ESC-based care pathways regardless of this debate.
Cluster RCT
Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal.
N Engl J Med. 2023;388(25):2326–2337.
PMID: 37125831
https://doi.org/10.1056/NEJMoa2214470
Post Hoc Subgroup Analysis
Influence of Eat, Sleep, and Console on Infants Pharmacologically Treated for Opioid Withdrawal: A Post Hoc Subgroup Analysis of the ESC-NOW Randomized Clinical Trial.
JAMA Pediatr. 2024;178(6):525–532.
PMID: 38619854
https://doi.org/10.1001/jamapediatrics.2024.0544
Review
Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.
Pediatrics. 2024;153(2):e2023062871.
PMID: 38178779
https://doi.org/10.1542/peds.2023-062871
Meta-Analysis
Eat, Sleep, Console Model for Neonatal Opioid Withdrawal Syndrome: A Meta-Analysis.
Front Pediatr. 2024;12:1416383.
PMID: 39220152
https://doi.org/10.3389/fped.2024.1416383
QI Cohort Study
Implementation of a Nurse-Driven Eat-Sleep-Console (ESC) Treatment Pathway at a Community Hospital for Treatment of Neonatal Opioid Withdrawal Syndrome in an Effort to Improve Short-term Outcomes.
Adv Neonatal Care. 2024;24(3):212–218.
PMID: 38127593
https://doi.org/10.1097/ANC.0000000000001123
Epidemiological Data Sources
Agency for Healthcare Research and Quality (AHRQ). HCUP Kids’ Inpatient Database (KID), 2016, 2019, 2022. Healthcare Cost and Utilization Project.
https://www.ahrq.gov/data/hcup/
AHRQ HCUP Fast Stats — NAS State-Level Rates 2018–2023.
https://datatools.ahrq.gov/hcup-fast-stats
Kaiser Family Foundation / T-MSIS Medicaid Analysis — Maternal OUD Estimates.
https://www.kff.org/medicaid/opioid-use-disorder-and-treatment-among-pregnant-and-postpartum-medicaid-enrollees/
Important Notice
This document is intended for healthcare professionals only. It is provided for informational and educational purposes. All clinical decisions should be made by qualified medical personnel in accordance with applicable clinical guidelines, institutional protocols, and individual patient circumstances. ESC study citations should be verified via PubMed (pubmed.ncbi.nlm.nih.gov) for final DOIs and full-text access. Prapela SVS must be used in accordance with its FDA-authorized indication and Instructions for Use. Prapela SVS is compatible with both Finnegan and ESC-based care pathways — clinicians should follow their institutional protocol for NOWS assessment and management.
This document is intended for healthcare professionals only. It is provided for informational and educational purposes. All clinical decisions should be made by qualified medical personnel in accordance with applicable clinical guidelines, institutional protocols, and individual patient circumstances. ESC study citations should be verified via PubMed (pubmed.ncbi.nlm.nih.gov) for final DOIs and full-text access. Prapela SVS must be used in accordance with its FDA-authorized indication and Instructions for Use. Prapela SVS is compatible with both Finnegan and ESC-based care pathways — clinicians should follow their institutional protocol for NOWS assessment and management.